Patents by Inventor Mostafa Hamed

Mostafa Hamed has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PqsR inverse agonists
    Patent number: 12528783
    Abstract: The present invention relates to a compounds according to general formula (I), which acts as an inverse agonist of PqsR (the currently only known receptor for the Pseudomonas Quinolone Signal (PQS), sometimes also referred to as MvfR); to a pharmaceutical composition containing one or more of the compound(s) of the invention; to a combination preparation containing at least one compound of the invention and at least one further active pharmaceutical ingredient; and to uses of said compound(s), including the use as a medicament, e.g. the use in the treatment or prophylaxis of a bacterial infection, especially a Pseudomonas aeruginosa or Burkholderia infection.
    Type: Grant
    Filed: December 30, 2020
    Date of Patent: January 20, 2026
    Assignee: HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH
    Inventors: Christian Schütz, Martin Empting, Ahmed S. Ahmed, Mostafa Hamed, Rolf W. Hartmann, Teresa Röhrig, Andreas M. Kany, Anna K. Hirsch
  • PqsR inverse agonists
    Patent number: 11883387
    Abstract: The present invention relates to a compound according to general formula (I), which acts as an inhibitor of PqsR (the currently only known receptor for the Pseudomonas Quinolone Signal (PQS)); to a pharmaceutical composition containing one or more of the compound(s) of the invention; to a combination preparation containing at least one compound of the invention and at least one further active pharmaceutical ingredient; and to uses of said compound(s), including the use as a medicament, e.g. the use in the treatment or prophylaxis of a bacterial infection, especially a Pseudomonas aeruginosa or Burkholderia infection.
    Type: Grant
    Filed: July 3, 2019
    Date of Patent: January 30, 2024
    Assignee: Helmholtz-Zentrum Für Infektionsforschung GmbH
    Inventors: Ahmed S. A. Ahmed, Martin Empting, Mostafa Hamed, Rolf W. Hartmann, Jörg Haupenthal, Thomas Hesterkamp, Ahmed A. M. Kamal, Christine K. Maurer, Teresa Röhrig, Christian Schütz, Samir Yahiaoui, Michael Zender
  • NEW PqsR INVERSE AGONISTS
    Publication number: 20230286942
    Abstract: The present invention relates to a compounds according to general formula (I), which acts as an inverse agonist of PqsR (the currently only known receptor for the Pseudomonas Quinolone Signal (PQS), sometimes also referred to as MvfR); to a pharmaceutical composition containing one or more of the compound(s) of the invention; to a combination preparation containing at least one compound of the invention and at least one further active pharmaceutical ingredient; and to uses of said compound(s), including the use as a medicament, e.g. the use in the treatment or prophylaxis of a bacterial infection, especially a Pseudomonasaeruginosa or Burkholderia infection.
    Type: Application
    Filed: December 30, 2020
    Publication date: September 14, 2023
    Inventors: Christian Schütz, Martin Empting, Ahmed S. Ahmed, Mostafa Hamed, Rolf W. Hartmann, Teresa Röhrig, Andreas M. Kany, Anna K. Hirsch
  • NOVEL PqsR INVERSE AGONISTS
    Publication number: 20230106506
    Abstract: The present invention relates to a compound according to general formula (I), which acts as an inverse agonist of PqsR (the currently only known receptor for the Pseudomonas Quinolone Signal (PQS), sometimes also referred to as MvfR); to a pharmaceutical composition containing one or more of the compound(s) of the invention; to a combination preparation containing at least one compound of the invention and at least one further active pharmaceutical ingredient; and to uses of said compound(s), including the use as a medicament, e.g. the use in the treatment or prophylaxis of a bacterial infection, especially a Pseudomonas aeruginosa or Burkholderia infection.
    Type: Application
    Filed: December 30, 2020
    Publication date: April 6, 2023
    Inventors: Mostafa Hamed, Ahmed S. Ahmed, Martin Empting, Christian Schütz, Rolf W. Hartmann, Teresa Röhrig, Andreas M. Kany, Anna K. Hirsch
  • Crystobactamides
    Patent number: 11225503
    Abstract: The present invention provides cystobactamides of formula (I): R1—Ar1-L1-Ar2-L2-Ar3-L3-Ar4-L4-Ar5—R2 and the use thereof for the treatment or prophylaxis of bacterial infections.
    Type: Grant
    Filed: June 10, 2020
    Date of Patent: January 18, 2022
    Assignee: HELMHOLTZ-ZENTRUM FÜR INFEKTIONSFORSCHUNG GMBH
    Inventors: Sascha Baumann, Jennifer Herrmann, Kathrin Mohr, Heinrich Steinmetz, Klaus Gerth, Ritesh Raju, Rolf Müller, Rolf W. Hartmann, Mostafa Hamed, Walid A. M. Elgaher, Maria Moreno, Franziska Gille, Liang Liang Wang, Andreas Kirschning, Stephan Huettel
  • PqsR INVERSE AGONISTS
    Publication number: 20210353606
    Abstract: The present invention relates to a compound according to general formula (I), which acts as an inhibitor of PqsR (the currently only known receptor for the Pseudomonas Quinolone Signal (PQS)); to a pharmaceutical composition containing one or more of the compound(s) of the invention; to a combination preparation containing at least one compound of the invention and at least one further active pharmaceutical ingredient; and to uses of said compound(s), including the use as a medicament, e.g. the use in the treatment or prophylaxis of a bacterial infection, especially a Pseudomonas aeruginosa or Burkholderia infection.
    Type: Application
    Filed: July 3, 2019
    Publication date: November 18, 2021
    Inventors: Ahmed S.A. Ahmed, Martin Empting, Mostafa Hamed, Rolf W. Hartmann, Jörg Haupenthal, Thomas Hesterkamp, Ahmed A.M. Kamal, Christine K. Maurer, Teresa Röhrig, Christian Schütz, Samir Yahiaoui, Michael Zender
  • CYSTOBACTAMIDES
    Publication number: 20200331964
    Abstract: The present invention provides cystobactamides of formula (I): R1—Ar1-L1-Ar2-L2-Ar3-L3-Ar4-L4-Ar5—R2 and the use thereof for the treatment or prophylaxis of bacterial infections.
    Type: Application
    Filed: June 10, 2020
    Publication date: October 22, 2020
    Inventors: Sascha Baumann, Jennifer Herrmann, Kathrin Mohr, Heinrich Steinmetz, Klaus Gerth, Ritesh Raju, Rolf Müller, Rolf W. Hartmann, Mostafa Hamed, Walid A. M. Elgaher, Maria Moreno, Franziska Gille, Liang Liang Wang, Andreas Kirschning, Stephan Huettel
  • Cystobactamides
    Patent number: 10793600
    Abstract: The present invention provides cystobactamides of formula (I) and the use thereof for the treatment or prophylaxis of bacterial infections.
    Type: Grant
    Filed: July 23, 2018
    Date of Patent: October 6, 2020
    Assignee: HELMHOLTZ-ZENTRUM FÜR INFEKTIONSFORSCHUNG GMBH
    Inventors: Sascha Baumann, Jennifer Herrmann, Kathrin Mohr, Heinrich Steinmetz, Klaus Gerth, Ritesh Raju, Rolf Müller, Rolf W. Hartmann, Mostafa Hamed, Walid A. M. Elgaher, Maria Moreno, Franziska Gille, Liang Liang Wang, Andreas Kirschning, Stephan Hüttel
  • Cystobactamides
    Patent number: 10519099
    Abstract: The present invention provides a method for the treatment or prophylaxis of bacterial infections by administering to a subject in need thereof an effective amount of a compound of formula.
    Type: Grant
    Filed: November 26, 2015
    Date of Patent: December 31, 2019
    Assignee: HELMHOLTZ-ZENTRUM FÜR INFEKTIONSFORSCHUNG GMBH
    Inventors: Sascha Baumann, Jennifer Herrmann, Kathrin Mohr, Heinrich Steinmetz, Klaus Gerth, Ritesh Raju, Rolf Müller, Rolf Hartmann, Mostafa Hamed, Walid A. M. Elgaher, Maria Moreno, Franziska Gille, Liang Liang Wang, Andreas Kirschning, Stephan Hüttel
  • CYSTOBACTAMIDES
    Publication number: 20190185514
    Abstract: The present invention provides cystobactamides of formula (I) and the use thereof for the treatment or prophylaxis of bacterial infections: R1—Ar1-L1-Ar2-L2-Ar3-L3-Ar4-L4-Ar5—R2??(I):
    Type: Application
    Filed: July 23, 2018
    Publication date: June 20, 2019
    Inventors: Sascha Baumann, Jennifer Herrmann, Kathrin Mohr, Heinrich Steinmetz, Klaus Gerth, Ritesh Raju, Rolf Müller, Rolf W. Hartmann, Mostafa Hamed, Walid A. M. Elgaher, Maria Moreno, Franziska Gille, Liang Liang Wang, Andreas Kirschning, Stephan Hüttel
  • NOVEL CYSTOBACTAMIDES
    Publication number: 20170327458
    Abstract: The present invention provides cystobactamides of formula (I) and the use thereof for the treatment or prophylaxis of bacterial infections.
    Type: Application
    Filed: November 26, 2015
    Publication date: November 16, 2017
    Applicant: HELMHOLTZ-ZENTRUM FÜR INFEKTIONSFORSCHUNG GMBH
    Inventors: Sascha Baumann, Jennifer Herrmann, Kathrin Mohr, Heinrich Steinmetz, Klaus Gerth, Ritesh Raju, Rolf Müller, Rolf Hartmann, Mostafa Hamed, Walid A. M. Elgaher, Maria Moreno, Franziska Gille, Liang Liang Wang, Andreas Kirschning, Stephan Hüttel
  • CYSTOBACTAMIDES
    Publication number: 20160145304
    Abstract: The present invention provides cystobactamides of formula (I) and the use thereof for the treatment or prophylaxis of bacterial infections:
    Type: Application
    Filed: July 14, 2014
    Publication date: May 26, 2016
    Inventors: Sascha Baumann, Jennifer Herrmann, Kathrin Mohr, Heinrich Steinmetz, Klaus Gerth, Ritesh Raju, Rolf Müller, Rolf Hartmann, Mostafa Hamed, Walid A.M. Elgaher, Maria Moreno, Franziska Gille, Liang Liang Wang, Andreas Kirschning